Meet the two cofounders who went on a 10-month-long trip before starting their $350 million business—they say you should too

Regard, an AI healthcare company founded by Nate Wilson and Eli Ben-Joseph, generated more than $150 million in revenue after its 2024 Series B valuation of $350 million. Wilson says the founders’ months of travel through China, the Philippines, and Colombia helped establish a partnership that later built the company, whose software analyzes medical records and is used in several hundred hospitals. The article focuses primarily on their founding experience rather than new financial or operating developments.

Analysis

This is founder-profile evidence, not underwriting evidence. A durable founding partnership may reduce execution risk, but it does not establish product differentiation, customer economics, or repeatable deployment. The key diligence gap is whether reported commercial traction reflects recurring, collected software revenue and sustained clinician use—or pilots, services, and a small number of large deployments. Verify revenue definition, renewal and expansion rates, customer concentration, implementation costs, and usage-linked outcomes before treating the company’s private valuation as validated.

For the broader market, the strategic prize is workflow ownership: clinical AI that reliably surfaces relevant information can become harder to displace when embedded in electronic health record systems. That also makes integration a competitive choke point. EHR incumbents such as Epic and Oracle Health, and documentation vendors such as Microsoft’s Nuance, can bundle adjacent functionality or control distribution; independent tools may face longer sales cycles and rising compliance and validation costs. Hospital counts alone are a weak proxy for economic adoption.

Near term, there is no clear public-market catalyst or investable security identified here. Over 1–3 months, seek independent evidence of deployments converting to paid, renewed contracts. Over 6–18 months, the thesis depends on measurable workflow use, retention, and clinical utility—not founder chemistry. A contrarian risk is that AI-health enthusiasm capitalizes announced reach before hospitals demonstrate durable budgets and clinician adoption. Thesis weakens if renewals or usage disappoint, implementation burden remains high, or EHR platforms bundle comparable tools.

Key Decisions for Investors

• No direct trade: Regard is presented as a private company and the article provides no independently verifiable financial or operating data. Do not translate the founder narrative into a public-equity signal.
• For private-market diligence, request revenue composition and collection data, paid-customer and renewal cohorts, expansion rates, customer concentration, deployment costs, and clinician usage/outcome measures; distinguish contracted recurring software revenue from pilots and services.
• Monitor EHR and clinical-AI vendors, including Epic, Oracle Health, and Microsoft’s Nuance, for bundling, distribution partnerships, and evidence that independent products can retain workflow access. Treat any public-market exposure as a watch item absent a company-specific catalyst.
• Falsifiers over the next 6–18 months: weak renewals or low active use despite broad deployment claims, rising implementation burden, or incumbent bundling that compresses independent vendors’ pricing and access.